First PhIII data with Lilly/Incyte's oral JAK inhibitor impresses in rheumatoid arthritis
This article was originally published in Scrip
Eli Lilly and Incyte's baricitinib has met the primary endpoint in the first Phase III data readout for the oral JAK inhibitor. The RA-BEACON study, in moderate to severe rheumatoid arthritis patients, showed baricitinib significantly improved ACR20 response compared to placebo after 12 weeks of treatment.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.